Bolt Biotherapeutics, Inc. Common Stock (BOLT)
Publicly reported company facts and saved market data for Bolt Biotherapeutics, Inc. Common Stock (BOLT), with sources and as-of times. Saved data is not a live quote.
Company profile
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics' pipeline reflects the Company's expertise in myeloid biology and cancer drug development. The Company's lead program is BDC-4182, a next-generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-4182 is currently in a Phase 1/2 trial that includes patients with gastric and gastroesophageal cancer. The Company has strategic collaborations with Genmab and Toray built around the Company's Boltbody ISAC platform technology. The rest of the Company's pipeline is currently on hold, including BDC-3042, a Dectin-2 agonist that completed a first-in-human Phase 1 dose escalation trial, as well as its preclinical ISAC programs targeting CEA and PD-L1.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $15.5M · as of
- Incorporated in
- United States
- Company website
- www.boltbio.com
- Exchange
- NASDAQ
FennEdge notes
Sessions where BOLT appeared in the Small-Cap Daily, newest first: opening gap, day change and the SEC filing or halt stored by the close. Facts with source links.
- #2 top gapper · gap +66.59% · closed +49.64% 8-K Private placement Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications
Related articles
Saved quote
Saved snapshot, not a real-time quote. Check the market time before relying on it.
- Last reported price
- $6.43
- Reported change
- +1.10%
- Reported volume
- 249,840
- Latest market time
Float and shares outstanding
| Measure | Shares | As of | Source and basis |
|---|---|---|---|
| Float F01 | 1,436,280 | Reported by a single source; not cross-checked. | |
| Historical float F02 | 1,000,000 | Historical estimate from the SEC-disclosed public float value; not current tradable shares. | |
| Shares outstanding (O/S) | 1,926,345 | SEC 10-Q filing · filed |
Dates are measurement dates, not the time FennEdge retrieved the data. Float references are listed separately; they are not averaged or adjusted for later splits or share issuances.
Short interest
- Reported short interest
- 25,736 shares
- Settlement date
- Source
- Market and company data
Exchange-published short interest for the stated settlement date, not a live short position.
Recent daily sessions
The 10 most recent saved daily sessions, through . Daily OHLC and volume; not real-time.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| 6.98 | 7.78 | 5.99 | 6.27 | 12,882,700 | |
| 4.06 | 4.21 | 4.03 | 4.19 | 14,054 | |
| 4.33 | 4.48 | 4.05 | 4.14 | 34,466 | |
| 4.05 | 4.33 | 4.05 | 4.31 | 29,274 | |
| 3.95 | 4.20 | 3.95 | 4.04 | 21,942 | |
| 4.46 | 4.48 | 3.96 | 4.00 | 10,118 | |
| 4.14 | 4.44 | 3.85 | 4.24 | 9,255 | |
| 4.28 | 4.38 | 3.76 | 3.98 | 31,070 | |
| 4.26 | 4.38 | 4.25 | 4.29 | 12,826 | |
| 4.13 | 4.68 | 4.13 | 4.24 | 28,728 |
Dilution timeline
As of
- · 8-K · Current report filed
Parsed share counts, prices and warrant terms require Plus or above. Explore plans
Research this company
FennEdge organizes SEC filings and reported market data. Sign in for additional research and your private trading context.
Sign in to continue